Bank Julius Baer & Co
CRVS icon

Bank Julius Baer & Co’s Corvus Pharmaceuticals CRVS Stock Holding History

Bank Julius Baer & Co’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-336,748
Closed -$1.04M – 831
2021
Q1 		$1.04M Buy
+336,748
New +$1.22M 0.01% 339

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bank Julius Baer & Co's CRVS Position: Q2 2021 in Review

Bank Julius Baer & Co sold out of Corvus Pharmaceuticals (CRVS) in Q2 2021, closing a stake of 336,748 shares — an estimated $1.04M sold.

Bank Julius Baer & Co first reported a position in CRVS in Q1 2021 and held it in 1 quarter. The position peaked at $1.04M in Q1 2021. 50 funds tracked by Wall St. Rank hold CRVS as of Q2 2021.

  • Bank Julius Baer & Co reported no remaining Corvus Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Bank Julius Baer & Co sold 336,748 Corvus Pharmaceuticals shares in Q2 2021, an estimated $1.04M.
  • Bank Julius Baer & Co first reported a position in Corvus Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Bank Julius Baer & Co's Corvus Pharmaceuticals position peaked at $1.04M in Q1 2021.
  • 50 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2021.

Based on Bank Julius Baer & Co's 13F filing for Q2 2021, filed 23 Jul 2021.